Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2009 1
2014 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

2 results

Results by year

Filters applied: . Clear all
Page 1
The phosphatidylinositol-protein nanocomplex as a new biosensor for ecological monitoring and clinical diagnostic.
Gilmanov MK, Kerimkulova AR, Sabitov AN, Ibragimova SA. Gilmanov MK, et al. Biosens Bioelectron. 2009 Jan 1;24(5):1490-2. doi: 10.1016/j.bios.2008.05.009. Epub 2008 Jul 7. Biosens Bioelectron. 2009. PMID: 18603423
The main feature of nanocomplex is its high sensitivity to ammonia ions. Linear response concentration for nanocomplex is from 0.5 microM to 10 microM ammonia ions. ...
The main feature of nanocomplex is its high sensitivity to ammonia ions. Linear response concentration for nanocomplex is from 0.5 mi …
[Ergoferon liquid dosage form--efficacious and safe treatment for childhood acute respiratory infections. Interim outcomes of a multi-center, randomized, double-blind, placebo-controlled clinical trial].
Geppe NA, Kondiurina EG, Galustian AN, Pak TE, Bal'tserovich NB, Zhiglinskaia OV, Kamaev AV, Lazareva SG, Laléko SL, Mel'nikova IM, Perminova OA, Sabitov AU. Geppe NA, et al. Antibiot Khimioter. 2014;59(5-6):6-14. Antibiot Khimioter. 2014. PMID: 25552038 Clinical Trial. Russian.
In Ergoferon group, the percentage of non-fever subjects, with the endpoint defined at 37.2 degrees C, was 43% on Day 2, as estimated in the morning and the evening (vs 25% and 19% in the placebo group, respectively; chi2 = 10.6; p = 0.012), and 83% in the morning and 84% in the …
In Ergoferon group, the percentage of non-fever subjects, with the endpoint defined at 37.2 degrees C, was 43% on Day 2, as estimated in the …